Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

1

Patients with relapsed/refractory multiple myeloma (RRMM) faced increased COVID-19 infection risk and higher mortality rates during the pandemic.
2

The phase 1/2 MajesTEC-1 study evaluated teclistamab in 165 patients, with most enrolled during peak COVID-19 infection rates.
3

COVID-19 infections occurred in 29.1% of patients, with 10.9% dying from the virus, highlighting the vulnerability of the MM population.
4

Vaccination against COVID-19 was associated with lower infection rates and mortality, emphasizing its importance for patients undergoing teclistamab treatment.
5

Median progression-free survival (PFS) was 11.3 months, while overall survival (OS) was 21.9 months, with improved outcomes when censoring for COVID-19 deaths.

Blood Cancer Journal

by Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani
October 21, 2024

1